All closing conditions satisfied for the acquisition of three small molecule sites in the US and Australia; closing to occur as of May 1, 2026. Adds highly demanded US-based manufacturing capacity to Siegfried's network.
India’s CDMO sector is rapidly advancing: stronger R&D, complex chemistry, digitalization, and efficiency gains. Astec boosts this with new R&D centers, automation, and global‑standard operations.
Evonik is expanding its biotechnological production capacities at the Fermas site in Slovenská Ľupča with an investment of around €80 million
Byphar is Brenntag's new biopharma-focused brand designed to bring quality, efficiency and flexibility to every stage of biopharmaceutical manufacturing.
Ofichem has unified its six brands under the single Ofichem name, creating a fully integrated, family-owned CDMO and pharmaceutical supplier.
Prange Pharma has completed its acquisition of MSD Animal Health’s Aprilia site in Italy, which will now operate as Aprilia Animal Health, a new European CDMO platform for the animal health sector.
On Demand | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.
Adragos Pharma has acquired Sanofi’s Maisons-Alfort sterile fill-finish site in France, expanding its European manufacturing network and prefilled syringe capabilities.
The acquisition marks Samsung Biologics’ geographical diversification, establishing its first US manufacturing presence and expanding regional client support.
As pharmaceutical production methods continue to evolve, flow chemistry is emerging as a safer, more scalable and selective alternative to conventional batch manufacturing.
Cambrex is advancing its $150 million investment to expand API manufacturing in Iowa and enhance R&D and manufacturing capabilities in Milan, strengthening its services in the US and Europe.
LGM Pharma invests an additional $9 million to expand US manufacturing, bringing total investment to $15 million across its Texas and Colorado facilities.
Ice Pharma recently announced a strategic expansion beyond its core API business, positioning the company to compete in higher-value finished dosage, nutraceutical, and specialty excipient markets.
Full-building, 15-year lease for 64,000 square feet enables CDMO CordenPharma Colorado to power next-generation peptide development in Boulder, Colorado.
$60 million investment to expand highly potent API (HPAPI) development and manufacturing at Axplora’s Farmabios site in Gropello Cairoli, Italy.
Sandoz has announced the creation of a new biosimilar development, manufacturing and supply unit.
Symbiosis Pharmaceutical Services has appointed experienced commercial leader Joanne Anderson as Chief Commercial Officer to drive global growth following recent capacity investments and expansion plans.
Lonza signs agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds, for an enterprise value of $3 billion (CHF 2.3 billion).
Forma Life Sciences launches as US-based contract development and manufacturing organization (CDMO) for oral solid dosage development and commercial manufacturing in Irvine, California.
As CROs and CDMOs expand their role in biopharma development and manufacturing, fast, accurate bioanalytic technologies remain critical to biotherapeutic affordability.
Axplora announced a multi-million-euro investment to expand lyophilization capabilities at its Le Mans site and appointed François Houbart as Head of Site.
Fujifilm Biotechnologies expanded manufacturing and process development presence in the North East of England to support vital biomanufacturing of innovative medicines and vaccines in the United Kingdom.
Veit Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology as well as automation in production from April 1, 2026.
WuXi Biologics partners with Sinorda on bispecific antibodies for autoimmune diseases and HanchorBio on fusion proteins for oncology and immunology.
Siegfried signed binding agreements to acquire three drug substance sites in the US and Australia.
Agno Pharma acquired Actylis's Eugene, Oregon CDMO facility, formerly Cascade Chemistry, for small-molecule API development and manufacturing, thereby expanding its US footprint.
How CDMOs are navigating uncertainty, forging partnerships, and embracing flexibility.
SOCMA’s 2026 Contract Manufacturing Outlook shows a resilient, innovative specialty chemical sector, with SMBs driving agility amid tariffs, regulatory complexity, and global uncertainty.
WuXi AppTec has agreed to sell its China-based clinical research services business, including WuXi Clinical and WuXi MedKey, to Hillhouse Investment Management.
Curia has completed a $4 million upgrade to its sterile API manufacturing suites in Valladolid, Spain, to enhance product quality, safety, and regulatory compliance.
Hovione has completed a $100 million investment to double spray-drying capacity and expand its East Windsor, New Jersey site, positioning the facility to meet growing US demand.
SK Pharmteco has announced a $6.1 million investment to expand its Rancho Cordova, California, facility with new lab and kilo-scale capabilities for solid-phase peptide synthesis and purification.
Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, announced that Orion has obtained an exclusive focused commercial license to one of Abzena’s mAbs..
ESIM Chemicals filed for bankruptcy proceedings at the Linz Regional Court in mid-October. The Austrian specialty chemicals company is heavily indebted.
Three-year outlook highlights investment in automation, cybersecurity, and regulated manufacturing as key drivers of long-term competitiveness.
